Legend: 
= Applied Session,
= Theme Session,
= Presenter, Sheraton Seattle Hotel & Towers = “S”
Washington State Convention & Trade Center = “CC”, Grand Hyatt Seattle = “H”
|
|
|
|
|
24
|
Sun, 8/6/06, 2:00 PM - 3:50 PM
|
CC-2A
|
|
Pharmacokinetics and Crossover Trials - Contributed - Papers
|
Biopharmaceutical Section, Biometrics Section, ENAR
|
|
Chair(s): Jie Chen, Merck Research Laboratories
|
|
2:05 PM
|
Assessing PK-AE Relationships Using Nonlinear Models —  Haiyuan Zhu, Merck Research Laboratories
|
|
2:20 PM
|
Applications of Adapted Crossover Designs To Reduce Study Cost and Length in Phase I Clinical Trials — Fang Liu, Merck Research Laboratories
|
|
2:35 PM
|
Analysis of Replicated Crossover Designs for Average Bioequivalence — Donna Kowalski, Astellas Pharma Inc.; Devan V. Mehrotra, Merck Research Laboratories
|
|
2:50 PM
|
Assessing Treatment Differences Adjusted by Possible Carryover Effects in Crossover Clinical Trials — Ling Chen, U.S. Food and Drug Administration
|
|
3:05 PM
|
Factorial Crossover Designs with Fewer Periods and Fewer Subjects — Sourav Santra, Northern Illinois University
|
|
3:20 PM
|
Locally D-Optimal Designs for Pharmacokinetics Compartmental Models — Xin Fang, University of Illinois at Chicago
|
|
3:35 PM
|
The Hypothesis Testing behind Steady State Determination in Clinical Pharmacology Trials — Bingming Yi, Merck & Co., Inc.; Xun Chen, sanofi-aventis; Patrick Larson, Merck & Co., Inc.
|
| |
